利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

90 条记录 (耗时 0.06 秒)

    Nucleic acids encoding humanized anti-tag 72 CC49 antbodies
    42.
    发明授权
    Nucleic acids encoding humanized anti-tag 72 CC49 antbodies 有权
    编码人源化抗标签72 CC49抗体的核酸

    公开(公告)号：US07919607B2

    公开(公告)日：2011-04-05

    申请号：US12474221

    申请日：2009-05-28

    申请人： Syed V. S. Kashmiri ,  Jeffrey Schlom ,  Eduardo A. Padlan

    发明人： Syed V. S. Kashmiri ,  Jeffrey Schlom ,  Eduardo A. Padlan

    IPC分类号： C07H21/04 ,  C12P21/04 ,  C12N7/00 ,  C12N15/00 ,  A61K39/395 ,  C07K16/00 ,  C12P21/08

    CPC分类号： C07K16/30 ,  A61K51/1045 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/92

    摘要： The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.

    摘要翻译： 本公开提供以高结合亲和力结合TAG-72并且是免疫原性最小的人源化CC49单克隆抗体。 在一个实施方案中，人源化CC49抗体包括CC49抗体的轻链互补决定区3中的非保守氨基酸取代。 在另一个实施方案中，人源化CC49抗体包括轻链互补决定区3中的第一残基的非保守取代和人源化CC49抗体的互补决定区的第二残基的取代。 在几个实施方案中，公开了使用人源化CC49抗体检测或治疗受试者的肿瘤的方法。 还公开了包含本文所述的人源化CC49抗体的试剂盒。

    Immunogenic peptides and methods of use
    43.
    发明授权
    Immunogenic peptides and methods of use 有权
    免疫原性肽及其使用方法

    公开(公告)号：US07910692B2

    公开(公告)日：2011-03-22

    申请号：US12280534

    申请日：2007-02-21

    申请人： Jeffrey Schlom ,  Kwong-Yok Tsang ,  Ira H Pastan

    发明人： Jeffrey Schlom ,  Kwong-Yok Tsang ,  Ira H Pastan

    IPC分类号： A61K38/00 ,  A61K48/00 ,  C07K7/00 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C07K14/4748 ,  A61K38/08 ,  A61K39/0011 ,  C07K14/82 ,  C12N2799/023 ,  C12N2800/00 ,  G01N2333/70517

    摘要： The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.

    摘要翻译： PAGE4基因在生殖组织中表达，并在生殖癌中表达，如前列腺癌，子宫癌和睾丸癌。 本文公开了免疫原性PAGE4多肽，以及编码免疫原性PAGE4多肽的核酸，包括这些多核苷酸的载体和用这些载体转化的宿主细胞。 这些多肽，多核苷酸，载体和宿主细胞可用于诱导对PAGE4的免疫应答。 还描述了检测PAGE4的诊断方法。

    Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
    46.
    发明授权
    Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes 失效
    用于产生CD8 +细胞毒性T淋巴细胞的突变型ras肽

    公开(公告)号：US07709002B1

    公开(公告)日：2010-05-04

    申请号：US09155590

    申请日：1997-04-17

    申请人： Jeffrey Schlom ,  Scott Abrams

    发明人： Jeffrey Schlom ,  Scott Abrams

    IPC分类号： A61K39/00 ,  A61K39/04 ,  A61K39/39 ,  A61K39/385 ,  A61K45/00 ,  C07K4/00

    CPC分类号： A61K45/06 ,  A61K39/00 ,  C07K14/82

    摘要： Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in-vivo-primed CD8+ CTL precursors.

    摘要翻译： 突变ras致癌基因肽可能在接种疫苗的患者中诱导特异性抗ras细胞免疫应答。 此外，鉴定了在密码子12反映K-ras致癌基因中的特异性点突变的人CD8 + CTL表位。 突变型ras肽对所选癌症患者的主动和被动免疫疗法都有影响。 鉴定了嵌合的10聚体肽[即ras5-14（Asp12）]，其显示与HLA-A2结合并显示用于扩增体内引发的CD8 + CTL前体的特异功能能力。

    MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES
    47.
    发明申请
    MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC T LYMPHOCYTES 审中-公开
    用于产生CD8 + CYTOTOXIC T淋巴细胞的突变RAP肽

    公开(公告)号：US20100074945A1

    公开(公告)日：2010-03-25

    申请号：US12623062

    申请日：2009-11-20

    申请人： Jeffrey Schlom ,  Scott Abrams

    发明人： Jeffrey Schlom ,  Scott Abrams

    IPC分类号： A61K9/127 ,  C07K7/06 ,  C07K7/08 ,  A61K38/08 ,  A61K38/10 ,  A61K35/12 ,  A61K38/20 ,  A61K38/21 ,  A61K38/16 ,  C12N5/00 ,  A61P35/00 ,  C07H21/00 ,  C12N15/63

    CPC分类号： C07K14/82 ,  A61K39/00

    摘要： Mutant ras oncogene peptides may induce specific anti-ras cellular immune responses in vaccinated patients. Moreover, a human CD8+ CTL epitope(s) reflecting a specific point mutation in the K-ras oncogene at codon 12 was identified. The mutant ras peptide has implications for both active and passive immunotherapies in selected carcinoma patients. A nested 10-mer peptide was identified [i.e., ras5-14(Asp12)], which was shown to bind to HLA-A2 and display specific functional capacity for expansion of the in vivo-primed CD8+ CTL precursors.

    摘要翻译： 突变ras致癌基因肽可能在接种疫苗的患者中诱导特异性抗ras细胞免疫应答。 此外，鉴定了在密码子12反映K-ras致癌基因中的特异性点突变的人CD8 + CTL表位。 突变型ras肽对所选癌症患者的主动和被动免疫疗法都有影响。 鉴定了嵌合的10聚体肽[即ras5-14（Asp12）]，其显示与HLA-A2结合并显示用于体内引发的CD8 + CTL前体扩增的特异功能能力。

    Method of enhancing a targeted immune response against tumors
    48.
    发明授权
    Method of enhancing a targeted immune response against tumors 有权
    增强针对肿瘤的靶向免疫应答的方法

    公开(公告)号：US07662395B2

    公开(公告)日：2010-02-16

    申请号：US12112819

    申请日：2008-04-30

    申请人： Jeffrey Schlom ,  Judith Kantor ,  James W. Hodge

    发明人： Jeffrey Schlom ,  Judith Kantor ,  James W. Hodge

    IPC分类号： A61K39/12

    CPC分类号： C07K14/70532 ,  A61K39/00 ,  A61K48/00 ,  C07K14/705 ,  C07K14/70503 ,  C12N2799/021 ,  C12N2799/023 ,  Y02A50/466

    摘要： The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.

    摘要翻译： 本发明是一种重组病毒的组合物，其在其基因组或其部分中掺入编码抗原的疾病引起剂和重组病毒，所述重组病毒在其基因组或其部分掺入了编码免疫刺激分子的基因， 目的是刺激针对疾病引发剂的免疫应答。 使用该组合物提供治疗由病原微生物引起的癌症和疾病等疾病的方法。

    Generation of immune response to prostate-specific antigen (PSA)
    49.
    发明授权
    Generation of immune response to prostate-specific antigen (PSA) 有权
    产生对前列腺特异性抗原（PSA）的免疫应答

    公开(公告)号：US07598225B1

    公开(公告)日：2009-10-06

    申请号：US09693121

    申请日：2000-10-20

    申请人： Jeffrey Schlom ,  Dennis L. Panicali

    发明人： Jeffrey Schlom ,  Dennis L. Panicali

    IPC分类号： A61K48/00

    CPC分类号： C07K14/4748 ,  A61K39/00 ,  A61K2039/5256 ,  A61K2039/55522 ,  A61K2039/55555 ,  C12N9/6445 ,  C12N2799/023 ,  C12N2799/026

    摘要： We have discovered that by using a recombinant viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding prostate-specific antigen (PSA), operably linked to a promoter capable of expression in the host, a specific humoral and cellular immune response to PSA can be generated. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate the immune response, and contacting the host with additional PSA at periodic intervals thereafter. The additional PSA may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional PSA can be added by contacting the host with PSA by a variety of other methods, including in one preferred embodiment adding PSA. The PSA may be formulated with an adjuvant or in a liposomal formulation.

    摘要翻译： 我们已经发现，通过使用重组病毒载体，优选具有至少一个含有编码前列腺特异性抗原（PSA）的DNA区段的插入位点的痘病毒载体，其可操作地连接到能够在宿主中表达的启动子，特异性体液 并且可以产生对PSA的细胞免疫应答。 该方法优选包括将足够量的重组痘病毒载体引入宿主以刺激免疫应答，并且此后以周期性间隔使宿主与另外的PSA接触。 可以通过使用来自不同痘属的第二痘病毒载体添加另外的PSA。 在另一个实施方案中，可以通过各种其它方法，包括在一个优选实施方案中添加PSA将宿主与PSA接触来添加另外的PSA。 PSA可以用佐剂或脂质体制剂配制。